Pamrevlumab Trials
Pamrevlumab Trials
Pamrevlumab, our proprietary fully human antibody, targets connective tissue growth factor (CTGF), the central mediator of tissue remodeling and fibrosis. Pamrevlumab represents a potential treatment for a broad array of fibrotic and proliferative disorders that affect organ systems throughout the body. Pamrevlumab is in Phase 3 clinical studies for the treatment of Duchenne muscular dystrophy and locally advanced pancreatic cancer.
Pancreatic Cancer
LAPIS Study – FG-3019-087, Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination with Gemcitabine Plus Nab-paclitaxel (G/NP) as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer
For more information on the study, please contact
Precision PromiseSM Platform Study, Phase 2/3, Randomized, Open-label, A Multi-Center Trial Evaluating Multiple Regimens in Patients with Stage IV Metastatic Pancreatic Cancer
For more information on this study, please visit